Deposition of apolipoproteins E and J in senile plaques is topographically determined in both Alzheimer's disease and Down's syndrome brain.
The link between the immunolocalization of apolipoproteins E (apo E) and J (apo J) and the different severity of beta-amyloid deposition in various areas of Alzheimer's disease (AD) and Down's syndrome (DS) brain was analyzed. Both apolipoproteins were found in all types of senile plaques (SPs) in the cerebral cortex, which is early and severely involved in beta-amyloidosis, but apo E was seen more often than apo J in diffuse A beta deposits, especially in young DS cases and nondemented elderly persons. In the striatum and cerebellum, which show predominance of diffuse A beta deposits throughout the lifespan, apo J was absent, except for few compact deposits, whereas apo E was more widely distributed, apart from diffuse plaques in the striatum. By immunoelectron microscopy, A beta fibrils were disclosed in diffuse plaques in all brain regions studied, but not all of these early fibrillar deposits, even in the neocortex of young DS cases, showed apo E and apo J labeling. Thus, our data indicate that the immunoreactivity to apo E and J within A beta deposits is topographically determined in both AD and DS brain. Moreover, although it appears that neither of apolipoproteins studied is necessary to initiate A beta fibrillogenesis, disclosed topographic dissimilarities of their distribution within parenchymal A beta deposits suggest that they may be involved in different ways in the pathogenesis of beta-amyloidosis.
Kida
E
E
New York State Institute for Basic Research in Developmental Disabilities, Department of Pathological Neurobiology, Staten Island 10314, USA.
Choi-Miura
N H
NH
Wisniewski
K E
KE
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000378:metabolism; D000544:Alzheimer Disease / Q000378:metabolism*; D001057:Apolipoproteins E / Q000032:analysis; D001923:Brain Chemistry / Q000502:physiology*; D001931:Brain Mapping / Q000379:methods*; D016022:Case-Control Studies; D002531:Cerebellum / Q000737:chemistry; D002540:Cerebral Cortex / Q000737:chemistry; D002648:Child; D051152:Clusterin; D003342:Corpus Striatum / Q000737:chemistry; D004314:Down Syndrome / Q000378:metabolism*; D006023:Glycoproteins / Q000032:analysis; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D018832:Molecular Chaperones; D009419:Nerve Tissue Proteins / Q000032:analysis*
D001057:Apolipoproteins E; C495242:CLU protein, human; D051152:Clusterin; D006023:Glycoproteins; D018832:Molecular Chaperones; D009419:Nerve Tissue Proteins